YM BioSciences Inc. is a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization. YM BioSciences is currently advancing three late-stage products: •CYT387: JAK 1/2 small molecule inhibitor initially targeting the treatment of a group of hematological disorders known as myeloproliferative neoplasms (MPNs), also known as myeloproliferative disorders. •Nimotuzumab: EGFR-targeting Affinity-Optimized Antibody™ in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation; approved for marketing in 25 countries. •CYT997: novel anti-cancer Vascular Disrupting Agent (VDA) in Phase II clinical development for the treatment of a variety of tumors.